Literature DB >> 8934453

Effect of sample storage on quantitation of lipoprotein(a) by an enzyme-linked immunosorbent assay.

R W Evans1, S S Sankey, B A Hauth, K Sutton-Tyrrell, M I Kamboh, L H Kuller.   

Abstract

This study evaluated the effect of storage on the quantitation of lipoprotein (Lp)(a) in 25 serum samples. Aliquots of serum were stored for up to three years at either -20 degrees C or -70 degrees C and Lp(a) subsequently analyzed using an enzyme-linked immunosorbent assay kit. Concentrations of Lp(a) declined during storage, and the temperatures employed elicited significantly different (P < 0.05) values within 12 mon which further diverged during three years of storage. Compared to baseline values, significant decreases (P < 0.05) in Lp(a) levels were evident after six months of storage at -20 degrees C with apparent losses (geometric mean) reaching 36.9% (95% confidence interval: 30.9%, 42.9%) after three years. Similarly, significantly lower (P < 0.05) Lp(a) values were recorded after six months of storage at -70 degrees C and at three years the decrease (geometric mean) was 19.1% (95% confidence interval: 14.3%, 24.0%). The losses, after three years, in terms of the arithmetic mean were 53.5 and 26.2% at -20 and -70 degrees C, respectively. Phenotype analysis suggested that large isoforms are more susceptible to degradation than smaller moieties. This may be related to the observation that apparent losses are reduced in samples containing over 8 mg/dL Lp(a). Nevertheless, Lp(a) levels in stored samples retained a strong correlation with the baseline values. These results must be considered specific for the storage conditions and analytical procedures employed.

Mesh:

Substances:

Year:  1996        PMID: 8934453     DOI: 10.1007/bf02524295

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  43 in total

1.  Interaction of serum lipoproteins with the hydroperoxide of methyl linoleate.

Authors:  T NISHIDA; F A KUMMEROW
Journal:  J Lipid Res       Date:  1960-10       Impact factor: 5.922

2.  Enzyme-linked immunoassay for Lp[a].

Authors:  G M Fless; M L Snyder; A M Scanu
Journal:  J Lipid Res       Date:  1989-05       Impact factor: 5.922

3.  Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a].

Authors:  J W Gaubatz; K I Ghanem; J Guevara; M L Nava; W Patsch; J D Morrisett
Journal:  J Lipid Res       Date:  1990-04       Impact factor: 5.922

4.  Lipoprotein(a) and peripheral atherosclerosis in older adults.

Authors:  K Sutton-Tyrrell; R W Evans; E Meilahn; H G Alcorn
Journal:  Atherosclerosis       Date:  1996-04-26       Impact factor: 5.162

5.  Reevaluation of serum-plasma differences in total cholesterol concentration.

Authors:  T Cloey; P S Bachorik; D Becker; C Finney; D Lowry; W Sigmund
Journal:  JAMA       Date:  1990 May 23-30       Impact factor: 56.272

6.  Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma.

Authors:  G Utermann; H J Menzel; H G Kraft; H C Duba; H G Kemmler; C Seitz
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

7.  Post-prandial Lp(a): identification of a triglyceride-rich particle containing apo E.

Authors:  A M Scanu; D Pfaffinger; C Edelstein
Journal:  Chem Phys Lipids       Date:  1994-01       Impact factor: 3.329

8.  The determination of lipoprotein Lp(a) by rate and endpoint nephelometry.

Authors:  G Cazzolato; G Prakasch; S Green; G M Kostner
Journal:  Clin Chim Acta       Date:  1983-12-15       Impact factor: 3.786

Review 9.  Lipoprotein(a). A potential bridge between the fields of atherosclerosis and thrombosis.

Authors:  A M Scanu
Journal:  Arch Pathol Lab Med       Date:  1988-10       Impact factor: 5.534

10.  Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants.

Authors:  M Jauhiainen; P Koskinen; C Ehnholm; M H Frick; M Mänttäri; V Manninen; J K Huttunen
Journal:  Atherosclerosis       Date:  1991-07       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.